Leerink Partnrs Estimates Gilead Sciences Q4 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities research analysts at Leerink Partnrs issued their Q4 2025 earnings per share estimates for Gilead Sciences in a research note issued on Wednesday, February 12th. Leerink Partnrs analyst D. Graybosch forecasts that the biopharmaceutical company will post earnings of $1.72 per share for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Gilead Sciences’ current full-year earnings is $4.35 per share.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%.

Other equities research analysts also recently issued research reports about the stock. Maxim Group downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Daiwa America raised Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. The Goldman Sachs Group increased their price target on Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a report on Wednesday. Mizuho raised their price objective on Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st. Finally, Sanford C. Bernstein started coverage on Gilead Sciences in a research report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 target price on the stock. Eleven analysts have rated the stock with a hold rating, fourteen have issued a buy rating and four have given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $101.33.

Gilead Sciences Trading Up 2.6 %

NASDAQ GILD opened at $105.96 on Friday. The stock has a market cap of $132.05 billion, a P/E ratio of 1,177.33, a PEG ratio of 1.25 and a beta of 0.18. The company’s fifty day simple moving average is $93.38 and its 200-day simple moving average is $87.24. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences has a 52 week low of $62.07 and a 52 week high of $106.43.

Institutional Trading of Gilead Sciences

Several hedge funds have recently added to or reduced their stakes in GILD. State Street Corp grew its stake in shares of Gilead Sciences by 1.4% in the third quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company’s stock worth $5,044,795,000 after purchasing an additional 841,776 shares in the last quarter. FMR LLC lifted its holdings in Gilead Sciences by 21.6% in the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company’s stock worth $3,724,306,000 after purchasing an additional 7,157,113 shares during the period. Wellington Management Group LLP grew its position in Gilead Sciences by 3.1% in the 4th quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company’s stock valued at $3,293,822,000 after buying an additional 1,058,331 shares in the last quarter. Geode Capital Management LLC increased its stake in Gilead Sciences by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company’s stock valued at $2,608,337,000 after buying an additional 749,047 shares during the period. Finally, Norges Bank bought a new stake in shares of Gilead Sciences during the 4th quarter worth about $1,789,254,000. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 248,645 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the sale, the chief financial officer now owns 138,919 shares of the company’s stock, valued at $12,886,126.44. This trade represents a 64.16 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the transaction, the director now directly owns 8,920 shares of the company’s stock, valued at $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 710,500 shares of company stock valued at $67,684,956. Insiders own 0.16% of the company’s stock.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.98%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. Gilead Sciences’s dividend payout ratio is presently 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.